Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
looks verry good
thanks
Shares Outstanding: 9.37M float 3,4M looks good too me
news and breakout comming
looks good too me
ATP-299 Strikes Oil on ACOR's ORRI - Five (5) More Oil Wells Completed on The Tintaburra Oil Field with Estimated Oil Reserves of approximately 84 Million Barrels of Oil or approximately $4.6 Billion Dollars at Current Market Prices
this is great news
THANKSSSSSSSSSSSSSSSSSSSSSSS
Hello
what do the chart say ??
Greetings
chart looking good
good news is comming
any comments on this one ???????
bottom play
running verry fast
China Health Holding Executed Letter of Intent to Acquire Xi'an Chunhui Pharmaceuticals
Monday December 4, 6:33 pm ET
LAS VEGAS--(BUSINESS WIRE)--China Health Holding (OTCBB: CHHH - News), a developer, manufacturer, marketer and distributor of pharmaceutical products and dietary supplements in China and worldwide, announced today that it has executed a binding acquisition letter of intent to acquire 51% or more ownership of Xi'an Chunhui Pharmaceuticals Co. Ltd., based in the People's Republic of China.
ADVERTISEMENT
The letter gives China Health first refusal and exclusive rights to complete the acquisition of Xi'an Chunhui Pharmaceuticals within 12 months of the execution date (that is, until November 27, 2007). The completion of the acquisition is subject to negotiation and execution of a definitive acquisition agreement, as well as full legal and financial due diligence. The latter includes the determination of the valuation of Xi'an Chunhui Pharmaceuticals and the completion and delivery of audited financial statements of Xi'an Chunhui Pharmaceuticals according to US General Accepted Accounting Principles ("US GAAP").
Julianna Lu, Founder/CEO of China Health Holdings, commented: "The acquisition contemplated by the letter of intent with Xi'an Chunhui Pharmaceuticals is the latest in a series of recent steps China Health has taken to execute its comprehensive growth strategy. Through this and other transactions, we are in the process of building a powerful network of established China-SFDA-certified pharmaceutical drug manufacturing facilities along with extensive hospital and drugstore distribution channels in China. We will also have an enhanced pipeline of hundreds of China-SFDA certified pharmaceutical drugs."
In addition to the pending Xi'an Chunhui Pharmaceuticals, China Health has announced several other pending or completed acquisitions of China-based pharmaceutical firms in recent months. It has executed letters of intent to acquire 51% or more of Beijing Boran Pharmaceutical Co. Ltd., Shaanxi Wanan Pharmaceuticals Co. Ltd.; and Henan Tiankang Pharmaceuticals Co. Ltd and all letters give China Health legal first refusal and exclusive rights. It has executed "Acquisition Definitive Agreements" for acquiring 100% of Shaanxi MeiChen Pharmaceuticals, Ltd. and 60% of Henan Furen Huaiqingtang Pharmaceuticals Co. Ltd. Also, it has signed a letter of intent with WangJing Hospital and the WangJing Hospital of China Academy of Chinese Medical Sciences, in the People's Republic of China, to develop the China International University of Traditional Chinese Medicine and the University Hospital for Traditional Chinese Medical Sciences.
In the next 12 to 24 months, China Health plans to complete further acquisitions and transactions with major pharmaceutical companies in the People's Republic of China, bringing its total assets to approximately US$100 million. At the end of this process, it projects annual gross revenue of approximately US$100 million, with annual net income of approximately US$10 million to US$15 million.
About Xi'an Chunhui Pharmaceuticals
Xi'an Chunhui Pharmaceuticals, based in Shaanxi Province, is a drug manufacturer, developer and distributor with good manufacturing practices (GMP) certification from the China State Food and Drug Administration (China-SFDA). It distributes a total of 50 China-SFDA certified herbal drugs to China-SFDA Licensed Hospitals and drugstores across Shaanxi province and the People's Republic of China. It also owns three China-SFDA certified pharmaceutical facilities and two China-SFDA certified pharmaceutical herbal/raw materials cultivation bases with unique advanced technologies.
Xi'an Chunhui Pharmaceuticals' herbal-based pharmaceutical drugs are used in treatment of cancers (such as liver and stomach cancer), viral infections, high blood pressure and cardiovascular disease.
If you would like to be added to China Health's investor email lists or have additional questions, please contact Haris Tajyar with Investor Relations International at htajyar@irintl.com, or/and info@chinahealthholding.com.
About China Health Holding
China Health Holding, Inc. is a developer, manufacturer and marketer for natural medicinal products and pharmaceutical drug pipeline in China and worldwide, with an extensive knowledge and expertise in the field of Traditional Chinese Medicine and China Pharmaceutical Industry. The Company's immediate goal is profitable penetration of the growing global and China pharmaceutical industry and market. Also to seek and develop and complete potential acquisition candidates with major pharmaceutical companies in PR China and worldwide to secure a strong future and powerful position in the global and PR China pharmaceutical industry. Long-term plans include the development of a pharmaceutical drug pipeline and technology based on the Company's access to the knowledge of Traditional Chinese Medicine and PR China pharmaceutical industry.
The Company is supported by two cores, wholly owned subsidiaries: 1. China Health World Pharmaceutical Corporation, which will develop, manufacture and commercialize natural medications for epidemic diseases and conditions related to mellitus, cardiovascular and cerebral-vascular system dysfunctions, and neurological disorders. 2. China Health World Trade Corporation, which will support the Company in the areas of worldwide to develop China Health’s retain/franchise stores/infrastructure and worldwide branding, multimedia marketing and multi-channel distribution to global customers and markets.
Recent Development and Acquisition Progress:
The Company controls/owns exclusive worldwide ownership/rights for a total of 134 proprietary natural herbal medicinal products/formulas as Two Natural Herbal Medicinal Product lines: King of Herbs products and Taoist Medicinal products. The Company is developing and execution for further worldwide branding, multimedia marketing and multi-channel distribution, and worldwide retail and franchise stores/infrastructure to global customers and markets.
CHHH has executed a definitive acquisition agreement to acquire 60% of Henan Furen Huaiqingtang Pharmaceuticals Co. Ltd, and CHHH has executed a definitive acquisition agreement to acquire 100% of Shaanxi MeiChen Pharmaceuticals Co. Ltd.
CHHH recently has also entered into acquisitions letters of intent to acquire 51% or more of the following pharmaceutical companies in PR China with legal first refusal and exclusive rights with: Beijing Boran Pharmaceutical Co. Ltd.; and Shaanxi Wanan Pharmaceuticals Co. Ltd.; and Henan Tiankang Pharmaceuticals Co. Ltd.
CHHH believes that the completion of these acquisitions will enable it to vertically integrate its operations from manufacturing, developing and marketing Chinese herbal-based medicinal products, as well as a pharmaceutical drug pipeline, to full distribution and marketing across PR China, therefore substantially increasing profit margins. Acquisitions should accelerate growth of revenues and earnings. A strategic combination of assets, net income, an enhanced pharmaceutical drug pipeline and technologies will accrete value to the Company and its shareholders.
In addition, CHHH also recently signed a letter of intent with WangJing Hospital and the WangJing Hospital of China Academy of Chinese Medical Sciences, PR China, in order to develop the China International University of Traditional Chinese Medicine and the University Hospital for Traditional Chinese Medical Sciences.
About Investor Relations International
Company: NewGen Technologies, Inc.
Ticker: NWGN
Profile Price: $0.39 September 5, 2006
Sold Price: Open profile
Gain (loss): n/a
Valuation: $15.21 million
Website: http://www.NWGNtech.com
Disclosure: Former client. We own shares.
Hot Points of Research and Analysis:
NewGen is an alternative fuel company that is focused on manufacturing, processing and distribution of advanced biofuels. Last year, they acquired three fuel terminals with total storage capacity of 10 million gallons and annual throughput capacity of over 500 million gallons. The three terminals are located in NC, SC and GA and are all scheduled to open during the first quarter of 2007. In addition, the company expects to begin construction on a new 60 million gallon biodiesel production facility in Georgia later this year.
Alternative fuels have been in the spotlight with various state and federal agencies passing various laws and acts to move America away from reliance on foreign oil and to reduce the pollution/emissions created by existing fuels.
What intrigues us about this stock now is the announcement they just made after the market closed on September 5, 2006. One of their subsidiaries (60% owned) acquired IPF Group based in Germany, which has 45 full-time employees and more than $30 million in annual revenue. Given that NewGen itself doesn't expect to generate revenue until next year, we think that this acquisition should have a material impact on the company and its stock price.
With 39 million shares currently outstanding and a closing stock price of $0.39, the company has a $15 million market value. Pre-revenue, that might make sense. Post-acquisition of the IPF Group...we think the stock has room to run.
looks verry good too me
chart looks verry good
news comming breakout
ano.ax A good nano company
www.advancednanotechnology.com
grsu.ob A low float oil investment company
I don"t know you can ask your friend
but what do you yhink of the company
whit a float about 2,4 mil shares
greetings
how much outstanding shares have this company
greetings